Episode
AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
- Published
- Mar 30, 2026
- Duration seconds
- 5362
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/akt-inhibition-in-prostate-cancer-proceedings-from-a-session-held-adjunct-to-the-2026-asco-genitourinary-cancers-symposium/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/akt-inhibition-in-prostate-cancer-proceedings-from-a-session-held-adjunct-to-the-2026-asco-genitourinary-cancers-symposium.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer. CME information and select publications here .